Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.
CPRX
$25.87
Name : Catalyst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,155,493,376.00
EPSttm : 1.57
finviz dynamic chart for CPRX
Catalyst Pharmaceuticals, Inc.
$25.87
2.01%
$0.51

Float Short %

6.7

Margin Of Safety %

31

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.07

EPS Last/This Y

0.72

EPS This/Next Y

0.25

Price

25.86

Target Price

34.29

Analyst Recom

1.14

Performance Q

17.81

Relative Volume

0.96

Beta

0.72

Ticker: CPRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08CPRX22.760.291.493919
2025-05-09CPRX23.340.590.905310
2025-05-12CPRX23.840.650.205518
2025-05-13CPRX23.650.660.205661
2025-05-14CPRX23.40.670.255621
2025-05-15CPRX23.770.670.005686
2025-05-16CPRX24.380.660.055694
2025-05-19CPRX24.630.260.832995
2025-05-20CPRX24.70.310.013280
2025-05-21CPRX24.310.270.143607
2025-05-22CPRX24.10.270.783660
2025-05-23CPRX24.480.280.033670
2025-05-27CPRX24.840.250.123972
2025-05-28CPRX24.540.250.424042
2025-05-29CPRX24.580.250.084044
2025-05-30CPRX24.970.250.324046
2025-06-02CPRX24.880.260.024177
2025-06-03CPRX24.910.260.004234
2025-06-04CPRX25.280.240.164436
2025-06-05CPRX25.340.270.134743
2025-06-06CPRX25.860.260.044923
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08CPRX22.7538.637.71.94
2025-05-09CPRX23.3417.918.12.39
2025-05-12CPRX23.8317.916.42.39
2025-05-13CPRX23.6517.98.02.39
2025-05-14CPRX23.3917.97.02.39
2025-05-15CPRX23.77-3.3-6.42.39
2025-05-16CPRX24.37-3.3-4.12.10
2025-05-19CPRX24.63-3.3-8.02.10
2025-05-20CPRX24.69-3.3-10.22.10
2025-05-21CPRX24.34-3.3-14.62.10
2025-05-22CPRX24.09-3.3-13.52.10
2025-05-23CPRX24.48-3.3-6.72.10
2025-05-27CPRX24.84-3.3-6.92.10
2025-05-28CPRX24.54-3.3-14.22.10
2025-05-29CPRX24.57-3.3-10.52.10
2025-05-30CPRX24.96-3.3-6.62.10
2025-06-02CPRX24.90-3.3-11.62.10
2025-06-03CPRX24.91-3.3-10.72.10
2025-06-04CPRX25.28-3.3-6.82.10
2025-06-05CPRX25.36-3.3-10.12.10
2025-06-06CPRX25.86-3.3-5.52.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08CPRX-10.33-0.877.01
2025-05-09CPRX-10.33-0.877.01
2025-05-12CPRX-10.33-0.987.21
2025-05-13CPRX-10.33-0.987.21
2025-05-14CPRX-6.53-0.987.21
2025-05-15CPRX-5.91-0.987.29
2025-05-16CPRX-6.69-0.987.29
2025-05-19CPRX-7.37-0.727.23
2025-05-20CPRX-7.20-0.727.23
2025-05-21CPRX-7.20-0.727.23
2025-05-22CPRX-5.86-0.727.23
2025-05-23CPRX-5.56-0.727.23
2025-05-27CPRX-5.56-0.947.23
2025-05-28CPRX-5.56-0.946.70
2025-05-29CPRX-5.56-0.946.70
2025-05-30CPRX-5.21-0.946.70
2025-06-02CPRX-5.210.516.70
2025-06-03CPRX-5.210.516.70
2025-06-04CPRX-5.210.516.70
2025-06-05CPRX-5.210.516.70
2025-06-06CPRX-5.210.516.70
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.45

Avg. EPS Est. Current Quarter

0.54

Avg. EPS Est. Next Quarter

0.52

Insider Transactions

-5.21

Institutional Transactions

0.51

Beta

0.72

Average Sales Estimate Current Quarter

140

Average Sales Estimate Next Quarter

138

Fair Value

33.78

Quality Score

93

Growth Score

100

Sentiment Score

80

Actual DrawDown %

1.1

Max Drawdown 5-Year %

-45.4

Target Price

34.29

P/E

16.51

Forward P/E

14.26

PEG

1.14

P/S

5.9

P/B

3.97

P/Free Cash Flow

11.79

EPS

1.57

Average EPS Est. Cur. Y​

2.1

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

36.91

Relative Volume

0.96

Return on Equity vs Sector %

0.8

Return on Equity vs Industry %

18.8

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

-0.06

EBIT Estimation

-5.5
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading